<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">In famitinib monotherapy, 3 (15%) patients exhibited PR, 1 (5%) patient had PD, and 16 (80%) patients had SD (Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>a–e). Overall, 12 (60%) patients demonstrated tumour shrinkage (from − 3.3% to− 33.3%, Fig. 
 <xref rid="Fig2" ref-type="fig">2</xref>e, f). 
</p>
